Regeneron Pharmaceuticals Inc (REGN)

Interest coverage

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before interest and tax (EBIT)	US$ in thousands	3,990,700	4,272,300	4,918,200	9,383,100	3,867,300
Interest expense	US$ in thousands	55,200	73,000	59,400	57,300	56,900
Interest coverage		72.30	58.52	82.80	163.75	67.97

December 31, 2024 calculation

Interest coverage = EBIT ÷ Interest expense
= $3,990,700K ÷ $55,200K
= 72.30

Based on the provided data, the interest coverage ratio of Regeneron Pharmaceuticals Inc has demonstrated fluctuations over the years.

As of December 31, 2020, the interest coverage ratio was 67.97, indicating that the company had a strong ability to cover its interest expenses with its earnings.

By December 31, 2021, the interest coverage ratio significantly improved to 163.75, suggesting a substantial increase in the company's ability to pay its interest obligations.

However, by December 31, 2022, the interest coverage ratio decreased to 82.80, although still at a healthy level, indicating that the company's earnings were sufficient to cover its interest expenses comfortably.

Subsequently, as of December 31, 2023, the interest coverage ratio dropped further to 58.52, indicating a slight reduction in the company's ability to cover its interest payments with its earnings.

At the end of December 31, 2024, the interest coverage ratio improved to 72.30, signifying a recovery in the company's ability to meet its interest obligations.

Overall, Regeneron Pharmaceuticals Inc has maintained a generally healthy interest coverage ratio throughout the years, although some fluctuations have been observed, likely due to changes in earnings and interest expenses. It is essential for investors and stakeholders to monitor this ratio to assess the company's financial health and ability to meet its debt obligations.